Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Impact of Brimonidine Tartrate Ophthalmic 0.025% on Patients Using Netarsudil 0.02%/Latanoprost 0.005% to Treat Glaucoma

NCT07209410 is registered in ClinicalTrials.gov with Insight Eyecare Specialties, Inc. dba Vision Source Eyecare, as lead sponsor.

NCT NCT07209410
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07209410 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Impact of Brimonidine Tartrate Ophthalmic 0.025% on Patients Using Netarsudil 0.02%/Latanoprost 0.005% to Treat Glaucoma
Lead sponsor
Insight Eyecare Specialties, Inc. dba Vision Source Eyecare,
Phase
Phase 4
Overall status
Recruiting
Start date
November 1, 2025
Completion date
June 1, 2027
Enrollment
35 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

glaucoma